Li Han
Researcher
Also affiliated: Qingdao University (2017–2018); University of Nebraska–Lincoln (2023); Fujian Medical University (2023–2025); Pennsylvania State University (2023); Zhejiang Sci-Tech University (2025); Howard Hughes Medical Institute (2025); North China University of Science and Technology (2025); University of Shanghai for Science and Technology (2022); University of Electronic Science and Technology of China (2024); Shandong University (2018); Sun Yat-sen University (2017–2021); Linyi University (2006); China Pharmaceutical University (2012–2025); Minnesota State University Moorhead (2013); University of Pittsburgh (2008); Hunan Normal University (2025); Shanxi Medical University (2021); Xuzhou Medical College (2015–2024); University of Dundee (2024); Shanghai Jiao Tong University (2011); Capital Medical University (2021); Dalian Medical University (2019–2020); Peking University (2003–2026); Huazhong Agricultural University (2009–2020); Sichuan University (2016); Southwest Forestry University (2020); University of Michigan (2023); Beijing Chao-Yang Hospital, Capital Medical University (2021); WellStar Kennestone Hospital (2025); XinHua Hospital (2011); Beijing Jishuitan Hospital (2026); Southwest Medical University (2024); University of Florida (2023–2024); Wuhan University (2012); Zhengzhou University (2011–2012); University of Chicago (2025); West China Hospital of Sichuan University (2016); Pathways Behavioral Services (1999); Zhoukou Normal University (2025); People 's Hospital of Jilin Province (2014); Central Arkansas Veterans Healthcare System (2016); Zhongda Hospital Southeast University (2017–2021); Affiliated Hospital of Xuzhou Medical College (2024); City of Hope (2019); Weifang People's Hospital (2018); Deltagen (United States) (2019); Nanyang Institute of Technology (2014–2026); Shandong Provincial Hospital (2018); Affiliated Hospital of Qingdao University (2017–2018); Sichuan Cancer Hospital (2024–2026); People's Hospital of Xinjiang Uygur Autonomous Region (2019); Heilongjiang Bayi Agricultural University (2025); Lanzhou University Second Hospital (2018–2022); Fujian Provincial People's Hospital (2023); National Center for Drug Screening (2012–2016); Zhoukou City Academy of Agricultural Sciences (2024–2025); The Affiliated Yongchuan Hospital of Chongqing Medical University (2022–2024); Peking University First Hospital (2003); Yanbian University Hospital (2021); Shanghai University of Medicine and Health Sciences (2019–2025); National Institute for Viral Disease Control and Prevention (2024); Institute of Information Technologies (2025); Second Affiliated Hospital of Jilin University (2018); Fujian Provincial Hospital (2023); Sun Yat-sen University Cancer Center (2017–2021); Baoji City Central Hospital (2024); Biostat (United States) (2019); Shanxi Academy of Medical Sciences (2021); Shandong Academy of Pharmaceutical Sciences (2011); Liaocheng People's Hospital (2025); Center for Life Sciences (2024); Affiliated Hospital of Jining Medical University (2021–2025); First Affiliated Hospital of Jinan University (2021); Shandong First Medical University (2021); S.P.E.C.I.E.S. (2024); Network Technologies (United States) (2025); University of York (2024); Tianjin Medical University (2016–2023); Ocean University of China (2006); Lanzhou University (2018–2022); Fuzhou University (2025); Chongqing Medical University (2022–2024); Guangzhou Medical University (2021); Florida College (2023–2024); Osmania Medical College (2024)
Faculty Researcher
Upstream record may be merged OpenAlex, the source of these figures, lists 86 institutions in 5 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Li Han's research focuses on cancer treatment, particularly exploring the efficacy of combination therapies and novel therapeutic targets. Han has investigated the use of sintilimab in combination with chemotherapy as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma, as documented in the ORIENT-16 phase III study. Additionally, Han's work includes studies on transarterial chemoembolization combined with lenvatinib and PD-1 inhibitors for hepatocellular carcinoma, with research aiming to predict early treatment response and overall prognosis in patients with portal vein tumor thrombus.
Further research interests include the molecular mechanisms underlying disease progression and therapeutic resistance. Han has published on the role of circRNA DOCK1 in modulating cell proliferation and apoptosis, and on the protooncogene TBL1XR1 as a potential cancer therapeutic target. Beyond oncology, Han has also explored the therapeutic potential of natural compounds, such as resveratrol, in alleviating pulmonary fibrosis by suppressing specific gene expression pathways.
With a scholarly output reflected in an h-index of 26 and over 2,600 citations across 153 publications, Han is recognized as a highly cited researcher. The lab maintains an active website, indicating ongoing research activities.
Metrics
- h-index: 26
- Publications: 154
- Citations: 2,683
Selected Publications
-
IRE1 signaling in osteoprogenitors augments β-catenin activity and physiologic bone accrual (2026)
Collaboration Network
Top Collaborators
- Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
- Th17 cell‐derived <i>miR‐155‐5p</i> modulates interleukin‐17 and suppressor of cytokines signaling 1 expression during the progression of systemic sclerosis
- FSTL1: A double-edged sword in cancer development
- Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases
- Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model
Showing 5 of 8 shared publications
- Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
- Th17 cell‐derived <i>miR‐155‐5p</i> modulates interleukin‐17 and suppressor of cytokines signaling 1 expression during the progression of systemic sclerosis
- FSTL1: A double-edged sword in cancer development
- Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases
- Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model
Showing 5 of 8 shared publications
- Detection of the gene mutation of epidermal growth factor receptor in lung adenocarcinoma by radiomic features from a small amount of PET data
- Correction: Applications of radiomics‑based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 17 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 5 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 10 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
Showing 5 of 8 shared publications
- Detection of the gene mutation of epidermal growth factor receptor in lung adenocarcinoma by radiomic features from a small amount of PET data
- Correction: Applications of radiomics‑based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 17 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 5 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 10 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
Showing 5 of 8 shared publications
- Detection of the gene mutation of epidermal growth factor receptor in lung adenocarcinoma by radiomic features from a small amount of PET data
- Correction: Applications of radiomics‑based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 17 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 5 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 10 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
Showing 5 of 8 shared publications
- Correction: Applications of radiomics‑based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 17 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 5 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 10 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 19 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
Showing 5 of 7 shared publications
- Correction: Applications of radiomics‑based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 17 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 5 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 10 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
- Additional file 19 of Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status
Showing 5 of 7 shared publications
- Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
- FSTL1: A double-edged sword in cancer development
- Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases
- Prediction and verification of the key ingredients and molecular targets of Guizhi Fuling capsule against tumour metastasis and resistance
- Chaperonin-containing TCP-1 subunit genes are potential prognostic biomarkers and are correlated with Th2 cell infiltration in lung adenocarcinoma: An observational study
Showing 5 of 6 shared publications
- Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
- Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
- The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
- Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
- Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
Showing 5 of 6 shared publications
- Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
- The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
- Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
- Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
- Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
- The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
- Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
- Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
- Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
- Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
- The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
- Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
- Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
- Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
- The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
- Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
- Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
- Th17 cell‐derived <i>miR‐155‐5p</i> modulates interleukin‐17 and suppressor of cytokines signaling 1 expression during the progression of systemic sclerosis
- Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model
- Prediction and verification of the key ingredients and molecular targets of Guizhi Fuling capsule against tumour metastasis and resistance
- Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
- FSTL1: A double-edged sword in cancer development
- Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model
Similar Researchers
Based on overlapping research topics